

```
acetylcholine, age-related decrease, 67
                                                     antipsychotics, 22, 33, 102
activities of daily living (ADL), 86, 89, 90
                                                     apathy, 43, 44, 101
aerobic exercise, 114-115
                                                     ApoE4 allele, 43, 76
age-related macular degeneration (AMD), 87
                                                     arthritis, 47
age-related sleep patterns, 74
                                                     attentional skills, delirium management, 22
Alzheimer's disease (AD)
                                                    axonal sprouting, 33
  aerobic exercise benefits, 114-115
  dental caries, 100
                                                     behavioural disturbances
  dysphagia, 46
                                                       in delirium, 19
  energy requirement increase, 45
                                                       falls associated, 7
  epilepsy as risk factor, 32
                                                       impact on oral health, 101
  falls association, 5, 7
                                                       weight loss and malnutrition, 44-45
  frailty, 112, 113, 114
                                                     benzodiazepines, 6, 22
  gait impairment, 5
                                                    bladder
  inflammation role in development, 101,
                                                       normal control/physiology, 61-62
                                                       overactive, 61, 66-67
       113-114
  late-onset, delirium in, 16
                                                     body mass index (BMI), 47, 113
  prediction, from frailty index, 114
                                                    brain structural changes, weight loss
  seizures, 30-31, 32, 34
                                                            and, 43, 45
     pathogenesis, 33
  sleep disturbances, 74, 75, 76
                                                    CADASIL, 88
                                                    carer stress/mental health problems, 80
  urinary incontinence, 62, 63
  visual dysfunction, 86
                                                    carers, burden of
    pathophysiology, 86, 87-88
                                                       oral health problems, 101
     symptoms/types, 90, 91
                                                       sleep disturbances, 80
  visual hallucinations, 91
                                                       urinary incontinence, 67-68
  visual variant (VVAD), 88
                                                       weight loss, 43
  visuospatial dysfunction, 90
                                                     case studies
                                                       delirium, 23
  weight loss and malnutrition, 40, 42
     causes, 43-45
                                                       epileptic seizures, 35-36
     nutritional supplementation, 47-48
                                                       fecal incontinence, 70
amyloid plaques, in retina, 88
                                                       falls, 10-11
amyloid precursor protein, 33
                                                       frailty, 115-116
anterior cingulate cortex (ACC), 45
                                                       oral disease, 106-107
anti-epileptic therapy, 34-35, 102
                                                       sleep disturbances, 81-82
antimuscarinic drugs, 66-67
                                                       urinary incontinence, 69-70
```

| visual dystunction, 93–94                   | dental hygiene/care see oral health;         |
|---|--|
| weight loss and malnutrition, 52            | oral hygiene                                 |
| cholinergic deficiency, 17                  | dental plaque, 99                            |
| cholinesterase inhibitors, 33               | dentistry, 105                               |
| falls associated, 7                         | minimal intervention, 105                    |
| sleep disturbances and, 76                  | dentures, 99, 100, 106                       |
| urinary incontinence and, 66                | detrusor hyperactivity, 61, 66-67            |
| weight loss and malnutrition, 46            | diarrhea, 61                                 |
| circadian rhythm changes, 74, 76, 77        | dietary intake, alterations, 43-44           |
| cognitive impairment                        | see also malnutrition                        |
| exercise program benefits, 114-115          | diffuse Lewy body disease (DLBD)             |
| falls associated, 3, 4                      | delirium vs dementia, 19                     |
| frailty association, 111, 112               | gait impairment and falls, 5, 7              |
| mild see mild cognitive impairment          | neurovascular instability, 6                 |
| visual acuity problems, 89                  | seizures, 31–32                              |
| colour vision impairment, 91                | urinary incontinence, 63                     |
| community                                   | donepezil, 66                                |
| activity programs, 79                       | Down syndrome, seizures, 32                  |
| fall reduction/prevention, 9                | drugs see medications                        |
| prompted voiding program, 66                | dual-tasking, 6                              |
| comorbidity, 1                              | dysphagia (swallowing difficulties), 43, 46  |
| in dementia, literature search, 1–2         | management/interventions, 50                 |
| Confusion Assessment Method (CAM), 20, 22   | management, meet venerens, e e               |
| constipation, 61, 68                        | Eating Behaviour Scale, 47                   |
| continence, 60–61, 63–64                    | eating environment, 48–49                    |
| see also urinary incontinence (UI)          | eating patterns, disordered, 43–44, 45       |
| continence aids, 67                         | education of staff, 48                       |
| contrast sensitivity, 88–89                 | delirium management, 22                      |
| Creutzfeldt–Jakob disease (CJD), 32, 88, 90 | dental hygiene, 105                          |
| Cieutzieitt-jakob disease (CJD), 32, 66, 90 | falls prevention, 8–9                        |
| down duck simulation (DDS) light            | nutritional supplementation, 47, 48          |
| dawn dusk simulation (DDS) light            |  |
| therapy, 77<br>daytime sleepiness, 75–76    | energy increased requirements, 45            |
| delirium, in dementia, 15–24                |  |
| assessment, 20–21                           | intake, timing, 49<br>enteral feeding, 50–51 |
|   | ě  |
| case studies, 23                            | hand feeding vs, 51                          |
| clinical features, 15, 18, 19–20            | environmental factors, nutritional intake    |
| definition, 15                              | improvement, 48–49                           |
| dementia cause/effect relationship, 16–17   | epileptic seizures (and epilepsy), 30–36     |
| diagnostic difficulties, 18, 20             | in AD see Alzheimer's disease                |
| epidemiology, 15–16                         | case studies, 35–36                          |
| etiology, 16–17                             | definition, 30                               |
| impact on dementia, 15, 18–19               | diagnosis, 34                                |
| management, 21–22                           | epidemiology and prevalence, 30–32           |
| mortality, 18                               | etiology, 33                                 |
| pathogenesis, 17                            | falls associated, 35                         |
| persistent, 15, 18, 20                      | features, 34                                 |
| prevention, in hospital, 21                 | management, 34–35                            |
| recommendations, 22-23                      | recommendations, 35                          |
| risk and risk factors, 15, 17-18, 19        | risk and risk factors, 31, 34                |
| Delirium Room, 21                           | as risk factor for dementia, 32–33           |
| dental caries, 99, 102                      | seizure types, 31, 34                        |
| epidemiology, 100, 101                      | in specific dementias/conditions, 31-3       |
| medications impact on, 102                  | treatment (drugs), 34-35                     |



| avarcica programs                                  | gait   |
|--|--|
| exercise programs delirium incidence reduction, 21 | gait   |
|  | impairment, 5<br>normal, 5                   |
| fall prevention, 9                                 | •  |
| frailty and cognitive decline reduction, 114–115   | see also walking                             |
| prompted voiding program with, 65–66               | gingival hyperplasia, 102                    |
| falls, in dementia, 3–11                           | glucose metabolism, 45                       |
| assessment, 8                                      | haloperidol, 21, 22                          |
| behavioural disturbances, 7                        | handgrip strength, decreased, 113            |
| case studies, 10–11                                | hemispatial neglect, 91                      |
| definition, 3                                      | hip fractures, 4, 19, 21                     |
| dementia pathology and, 5, 6                       | hippocampal lesions, falls and, 5            |
| epidemiology, 3–4                                  | hospitalization                              |
| etiology, 4–5                                      | after falls, 4                               |
| gait impairment, 5                                 | delirium precipitation, 16-17, 18            |
| management, 8–9                                    | delirium prevention, 21                      |
| medication effects, 6-7, 9                         | protein/energy intake reduced,               |
| preventative interventions, 8-9, 10                | interventions, 50                            |
| recommendations, 10                                | Huntington's disease, seizures, 32           |
| risk and risk factors, 3, 7, 8                     | hyberbolic state, 45                         |
| seizures associated, 35                            | hypotension, orthostatic (postural), 6       |
| sequelae/effects, 3, 4                             | 7  |
| fecal impaction with overflow, 61, 68              | incontinence, 60–70                          |
| fecal incontinence, 61, 68                         | see also fecal incontinence; urinary         |
| case study, 70                                     | incontinence (UI)                            |
| epidemiology, 62                                   | incontinence pads/aids, 67                   |
| management, 68                                     | individualized social activity interventions |
| prevalence, and risk factors, 68                   | (ISAI), 79                                   |
| feeding, enteral see enteral feeding               | indwelling catheter (IDC), 67                |
| feeding behaviour changes, 44                      | inflammation, 101, 113–114                   |
| fibre (dietary), intake, 68                        |  |
| finger foods, 49                                   | lean body mass, reduced, 113                 |
| food(s)  | levetiracetam, 35                            |
| familiar, and familiar environment                 | light therapy, 77                            |
| for, 48-49   | melatonin with, 78                           |
| finger, 49   |  |
| refusal, 44  | macular retinal nerve fibre layer, 87        |
| types, to improve eating/nutrition, 49             | macular volume, reduction, 87                |
| frailty, 111–116                                   | malnutrition, 40                             |
| case studies, 115–116                              | assessment, 47, 51                           |
| causes, 111  | behavioral symptoms                          |
| definition/criteria, 111, 112                      | associated, 44-45                            |
| epidemiology, 111–113                              | case studies, 52                             |
| etiology, 113–114                                  | causes/pathogenesis, 41, 42-46               |
| management, 114–115                                | dementia impact, 40-42                       |
| as noncognitive feature of AD, 114                 | disordered eating patterns, 43-44            |
| recommendations, 115                               | dysphagia, 46                                |
| frontotemporal dementia (FTD)                      | intervention and management, 46, 47-51       |
| dysphagia, 46                                      | in nursing home residents, 41                |
| eating pattern changes, 43-44                      | recommendations for management, 51-52        |
| urinary incontinence, 63-64                        | see also weight loss                         |
| weight loss and malnutrition, 40                   | meals, 49-50                                 |
| functional incontinence, 61                        | medial temporal lobe, abnormalities, 45      |
|  |  |

| medications falls associated, 6–7, 9 impact on oral health, 102–103 seizure threshold reduced, 33 for sleep disturbances, 77–78 for urinary incontinence, 66–67 weight loss/malnutrition association, 46 melatonin deligium management, 22 | oral hygiene daily care recommendations, 104, 106 poor state, 99, 100 staff education on, 105 oral ulceration, 102 orthostatic hypotension, 6 oxybutynin, 66–67 Parkinson's disease |
|--|---|
| delirium management, 22<br>sleep disturbance intervention, 78  |   |
| mild cognitive impairment (MCI)  | dysphagia, 46<br>gait impairment and falls, 5, 7  |
| frailty and reduced motor function,  | neurovascular instability, 6  |
| 112  | urinary incontinence, 63  |
| retinal nerve fibre layer, 87  | pelvic floor exercises, 66  |
| sleep pattern changes, 75, 81–82   | perceptual disturbances, 19   |
| Mini Nutritional Assessment (MNA), 47  | percutaneous endoscopic gastrostomy (PEG)   |
| mouthwash, 104   | tubes, 50–51  |
| multitasking (dual-tasking), 6   | periodontal disease, 102  |
| muscle strength decrease, 111, 113   | physical activity   |
|  | increased nutritional intake, 50  |
| nasogastric tubes, 50  | sleep disturbance management, 79  |
| National Institute of Clinical Excellence,   | see also exercise programs  |
| delirium diagnosis, 20   | physical restraints, fall prevention, 9   |
| neurofibrillary tangles, 75  | polysomnography, 76   |
| neuroleptics, falls associated, 6  | postural hypotension, 6   |
| neurovascular instability, 6   | prompted voiding (PV) programs, 65–66   |
| night monitoring system (NMS), 80  | design and goals, 65  |
| nursing homes and residential care   | outcome and resource requirements,  |
| malnutrition in, 41  | 65–66, 68   |
| oral hygiene and dental care, 105  | DEM alaam daamaaa 75 76   |
| urinary incontinence prevalence, 62  | REM sleep, decrease, 75, 76 residential care <i>see</i> nursing homes and   |
| visual impairment, 92<br>nutritional disorders <i>see</i> malnutrition; weight   | residential care  |
| loss   | respite care, 80  |
| nutritional state, dementia impact, 40–42  | restlessness, night time, walking impact, 79  |
| nutritional supplementation, 47–48, 50   | retinal nerve fibre layer (RNFL), thickness, 87   |
|  | risperidone, 78   |
| optic flow, impairment, 91   | 1   |
| optic nerve, changes, 87   | saliva, reduced, 102  |
| oral disease, 99-107   | saliva stimulators, 106   |
| assessment, 104, 105   | sedation, in dentistry, 105   |
| case studies, 106–107  | sedatives, 77   |
| epidemiology, 100  | seizures see epileptic seizures (and epilepsy)  |
| management, 103  | sialorrhea, 102   |
| symptoms and signs, 103  | sleep   |
| treatment, 104–105   | age-related changes, 74   |
| oral health  | deprivation in carers, 80   |
| behavioural changes impact, 101  | sleep disturbances in dementia, 74–82   |
| benefits, 99   | carer burden, 80  |
| goals, 103–104   | case studies, 81–82   |
| impact of dementia on, 100–102   | epidemiology, 75–77   |
| medication impact on, 102–103  | intervention and treatment, 77–79   |
| recommendations, 106   | pathology, 74–75  |



| sleep disturbances in dementia (cont.) | definition, 86                               |
|--|--|
| recommendations, 81                    | features/types, 88-91                        |
| types, 76                              | impact in dementia, 88                       |
| stress incontinence, 61                | interventions, 93                            |
| sucking reflexes, 102                  | pathology, 86-88                             |
| sundowning, management, 22             | recommendations, 92, 93                      |
| swallowing problems see dysphagia      | in residential care, 92                      |
| synaptic hyperactivity, 33             | types of visual problem, 86, 88              |
|  | visual field defects, 86, 89-90              |
| 'talking while walking' test, 6        | visual hallucinations, 88, 91-92             |
| teeth                                  | visual motion, optic flow impairment and, 91 |
| low number, dementia association, 101  | visuospatial dysfunction, 90                 |
| preservation, benefits, 105            |  |
| •                                      | walking                                      |
| urge incontinence, 61                  | impact on nighttime restlessness, 79         |
| urinary incontinence (UI), 8, 60-70    | speed decrease, frailty, 111, 112            |
| assessment, 64                         | see also gait                                |
| caregiver burden, 67-68                | wandering, falls and, 7                      |
| case studies, 69–70                    | weight                                       |
| causes, 60, 63, 64, 66                 | dementia impact on, 40-42                    |
| definition, 60                         | gain, 42, 46                                 |
| dementia types and, 62, 63-64          | weight loss, 40–53                           |
| epidemiology, 62                       | assessment, 47, 51                           |
| impact of dementia on, 63-64           | behavioural symptoms and, 44-45              |
| intervention and management, 64-68     | case studies, 52                             |
| continence aids, 67                    | causes/pathogenesis, 41, 42-46               |
| medications, 66-67                     | cholinesterase inhibitors, 46                |
| PV program see prompted voiding (PV)   | dietary intake alterations, 43-44            |
| programs                               | disordered eating patterns, 43-44            |
| prevalence and increase in, 60, 62     | epidemiology and prevalence, 42              |
| recommendations, 69                    | frailty and, 113                             |
| stress incontinence, 61                | increased energy needs, 45                   |
| types, 61                              | intervention and management, 46,             |
| urinary obstruction with overflow, 61  | 47–51  |
| •                                      | education of staff, 48                       |
| vascular dementia                      | enteral feeding, 50-51                       |
| delirium in, 16                        | environmental factors, 48-49                 |
| gait impairment and falls, 5           | multifactorial strategy, 49-50               |
| urinary incontinence, 62               | nutritional supplementation, 47-48           |
| weight loss and malnutrition, 40       | targeted approaches, 49-50                   |
| visual acuity impairment, 89, 91       | preceding dementia, 41-42                    |
| recommendations, 92                    | recommendations for management, 51-52        |
| visual dysfunction, 86-94              | Ž  |
| assessment, 87, 92                     | xerostomia (dry mouth), 99, 100, 101         |
| case studies, 93-94                    | drugs causing, 102                           |
|  |  |